The role of erythropoietin and erythropoietin receptor expression in breast cancer

被引:0
|
作者
Budzik, M. P. [1 ]
Badowska-Kozakiewicz, A. M. [1 ]
机构
[1] Med Univ Warsaw, Dept Biophys & Human Physiol, Fac Hlth Sci, Warsaw, Poland
关键词
Breast neoplasms; Erythropoietin; Hypoxia; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RECOMBINANT-HUMAN-ERYTHROPOIETIN; GENE-EXPRESSION; CELL CARCINOMA; EPO RECEPTOR; SURVIVAL; ANEMIA; GROWTH; STAT3; MIGRATION;
D O I
10.12892/ejgo4266.2019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Erythropoietin (EPO) plays a number of important functions in the body. Contrary to original beliefs, its activity is not limited to exerting effects on cells along the erythropoietic pathway. Newly published results continue to provide information on novel functions of the protein in other types of tissues, as well as on the important roles played by EPO in pathological processes. With no doubt, EPO has a significant impact on the biology of breast cancer cells by affecting cells' proliferation, apoptosis, resistance to chemotherapy, as well as expression of various types of receptors. EPO exerts its direct action on breast cancer stem-like cells by activation of specific signaling pathways responsible for protection of the tumor from chemotherapy and accelerating disease progression. EPO could inhibit chemotherapeutic drug-induced apoptosis and cytotoxicity. Its correlation with tissue hypoxia may play a significant role in the therapeutic resistance of hypoxic tumors. In recent years, the role of endogenous EPO in regulation of carcinogenesis was also noted. Exogenous EPO, in the form of rhEPO, had been introduced with best intention to treat patients with cancer-related anemia in the course of breast cancer. While it decreases the transfusion requirements and improves the quality of life of cancer patients, randomized trials have demonstrated that rhEPO administration is associated with shorter progression-free and overall survival. Observations allow also to say that EPO antagonizes treatment with the anti-HER2 antibody trastuzumab by activating EpoR/JAK2 downstream effectors, effectively bypassing HER2 signaling. Although increasing amount of information is available regarding the role of EPO and EpoR in breast cancer, elucidation of the activity and involvement of these proteins in complex processes occurring within the cancer cells requires extensive research. Every set of results being published answers some of the questions while instead raise new ones.
引用
收藏
页码:7 / 15
页数:9
相关论文
共 50 条
  • [21] Expression and functional significance of the erythropoietin receptor in hepatocellular carcinoma
    Shin, Milljae
    Hong, Doopyo
    Zhang, Zhengyun
    Kim, You Min
    Lee, Wookjong
    Joh, Jae-Won
    Kim, Sung-Joo
    HPB, 2013, 15 (12) : 965 - 975
  • [22] Erythropoietin drives breast cancer progression by activation of its receptor EPOR
    Chan, Ka Kui
    Matchett, Kyle B.
    Coulter, Jonathan A.
    Yuen, Hiu-Fung
    McCrudden, Cian M.
    Zhang, Shu-Dong
    Irwin, Gareth W.
    Davidson, Matthew A.
    Ruelicke, Thomas
    Schober, Sophie
    Hengst, Ludger
    Jaekel, Heidelinde
    Platt-Higgins, Angela
    Rudland, Philip S.
    Mills, Ken I.
    Maxwell, Perry
    El-Tanani, Mohamed
    Lappin, Terence R.
    ONCOTARGET, 2017, 8 (24): : 38251 - 38263
  • [23] Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor
    Castillo Hernandez, Carolina
    Felipe Burgos, Carlos
    Hidalgo Gajardo, Angela
    Silva-Grecchi, Tiare
    Gavilan, Javiera
    Roberto Toledo, Jorge
    Fuentealba, Jorge
    NEURAL REGENERATION RESEARCH, 2017, 12 (09) : 1381 - 1389
  • [24] The erythropoietin receptor in normal and cancer tissues
    Jelkmann, Wolfgang
    Bohlius, Julia
    Hallek, Michael
    Sytkowski, Arthur J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 67 (01) : 39 - 61
  • [25] Expression of erythropoietin receptor splice variants in human cancer
    Arcasoy, MO
    Jiang, XH
    Haroon, ZA
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 307 (04) : 999 - 1007
  • [26] Recombinant human erythropoietin alters gene expression and stimulates proliferation of MCF-7 breast cancer cells
    Trost, Nina
    Stepisnik, Tina
    Berne, Sabina
    Pucer, Anja
    Petan, Toni
    Komel, Radovan
    Debeljak, Natasa
    RADIOLOGY AND ONCOLOGY, 2013, 47 (04) : 382 - 389
  • [27] Glioblastoma multiforme cells: Expression of erythropoietin receptor and response to erythropoietin
    Yin, Dong
    Kawabata, Hiroshi
    Tcherniamtchouk, Oxana
    Huynh, Thien
    Black, Keith L.
    Koeffler, H. Phillip
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 31 (05) : 1193 - 1198
  • [28] The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer
    Hu, Weiling
    Zhang, Yu
    Jiang, Zhinong
    Wang, Lan
    Li, Jun
    Chen, Shujie
    Dai, Ning
    Si, Jianmin
    TUMOR BIOLOGY, 2016, 37 (08) : 11523 - 11533
  • [29] Erythropoietin and erythropoietin receptor expression in the guinea pig inner ear
    Cayé-Thomasen, P
    Wagner, N
    Frederiksen, BL
    Asal, K
    Thomsen, J
    HEARING RESEARCH, 2005, 203 (1-2) : 21 - 27
  • [30] Effect of fetal bovine serum on erythropoietin receptor expression and viability of breast cancer cells
    Teo, Guan-Young
    Rasedee, Abdullah
    AL-Haj, Nagi A.
    Beh, Chaw Yee
    How, Chee Wun
    Rahman, Heshu Sulaiman
    Alitheen, Noorjahan Banu
    Rosli, Rozita
    Abdullah, Al-Shwyeh Hussah
    Ali, Abdelwahid Saeed
    SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2020, 27 (02) : 653 - 658